Tango Therapeutics (TNGX) Retained Earnings (2020 - 2026)
Tango Therapeutics (TNGX) posted quarterly Retained Earnings of -$115000.0 for Q1 2026, down 159.28% year-over-year from $194000.0 in Q1 2025, and down 100.01% quarter-over-quarter from $949.0 million in Q4 2025.
Tango Therapeutics (TNGX) Retained Earnings (2020 - 2026) Analysis & Trends
Tango Therapeutics' Retained Earnings history runs 7 years deep, the most recent figure standing at -$115000.0 for Q1 2026.
- In Q1 2026, Retained Earnings fell 159.28% year-over-year to -$115000.0; the TTM figure through Mar 2026 stood at -$115000.0 (down 159.28% YoY), while the FY2025 annual figure was $949.0 million, up 282331.85% from the prior year.
- Retained Earnings for Q1 2026 stood at -$115000.0, down from $949.0 million in the prior quarter.
- The five-year high for Retained Earnings was $949.0 million in Q4 2025, with the low at -$269.5 million in Q4 2022.
- The 5-year median for Retained Earnings is $194000.0 (2025), against an average of $187.4 million.
- The sharpest annual moves came in 2022 and 2025: Retained Earnings sank 2404420.0% in 2022, then jumped 282331.85% in 2025.
- Tango Therapeutics' Retained Earnings stood at -$269.5 million in 2022, then soared by 100.07% to $186000.0 in 2023, then soared by 80.65% to $336000.0 in 2024, then surged by 282331.85% to $949.0 million in 2025, then slumped by 100.01% to -$115000.0 in 2026.
- Business Quant data shows TNGX's Retained Earnings at -$115000.0 in Q1 2026, $949.0 million in Q4 2025, and $121000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Tango Therapeutics | 4.32 Bn | 3.30 Bn | - | 1.73 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.73 Bn |
| Mar 31, 2026 | -115,000.00 |
| Dec 31, 2025 | 948.97 Mn |
| Sep 30, 2025 | 121,000.00 |
| Jun 30, 2025 | 715.04 Mn |
| Mar 31, 2025 | 194,000.00 |
| Dec 31, 2024 | 336,000.00 |
| Sep 30, 2024 | 750,000.00 |
| Jun 30, 2024 | -334,000.00 |
| Mar 31, 2024 | 673.77 Mn |
| Dec 31, 2023 | 186,000.00 |
| Sep 30, 2023 | -681,000.00 |
| Jun 30, 2023 | 532.60 Mn |
| Mar 31, 2023 | 526.90 Mn |
| Dec 31, 2022 | -269.51 Mn |
| Sep 30, 2022 | -240.45 Mn |
| Jun 30, 2022 | -211.40 Mn |
| Mar 31, 2022 | 510.22 Mn |
| Dec 31, 2021 | -161.34 Mn |
| Sep 30, 2021 | -10,000.00 |